You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 Chunxia Li -- 3132 2022-12-17 10:48:14 |
2 format correct Jessie Wu + 15 word(s) 3147 2022-12-19 04:35:13 | |
3 format correct Jessie Wu + 4 word(s) 3151 2022-12-19 04:38:18 | |
4 format correct Jessie Wu + 3 word(s) 3154 2022-12-19 04:40:14 |

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Bai, Y.;  Wang, H.;  Author）, C.L. SAP90/PSD-95-Associated Protein Scaffold Proteins and Neuropsychiatric Disorders. Encyclopedia. Available online: https://encyclopedia.pub/entry/38915 (accessed on 14 December 2025).
Bai Y,  Wang H,  Author） CL. SAP90/PSD-95-Associated Protein Scaffold Proteins and Neuropsychiatric Disorders. Encyclopedia. Available at: https://encyclopedia.pub/entry/38915. Accessed December 14, 2025.
Bai, Yunxia, Huimin Wang, Chunxia Li（*Corresponding Author）. "SAP90/PSD-95-Associated Protein Scaffold Proteins and Neuropsychiatric Disorders" Encyclopedia, https://encyclopedia.pub/entry/38915 (accessed December 14, 2025).
Bai, Y.,  Wang, H., & Author）, C.L. (2022, December 17). SAP90/PSD-95-Associated Protein Scaffold Proteins and Neuropsychiatric Disorders. In Encyclopedia. https://encyclopedia.pub/entry/38915
Bai, Yunxia, et al. "SAP90/PSD-95-Associated Protein Scaffold Proteins and Neuropsychiatric Disorders." Encyclopedia. Web. 17 December, 2022.
SAP90/PSD-95-Associated Protein Scaffold Proteins and Neuropsychiatric Disorders
Edit
This entry is adapted from the peer-reviewed paper 10.3390/cells11233815

The SAPAP (SAP90/PSD-95-associated protein, also called discs-large-associated proteins (DLGAPs)) family is made up of key postsynaptic scaffold proteins that are highly concentrated in the PSD of excitatory synapses and are essential for synaptic structure and functions. Excitatory (glutamatergic) synaptic transmission underlies many aspects of brain activity and the genesis of normal human behavior. The postsynaptic scaffolding proteins SAP90/PSD-95-associated proteins (SAPAPs), which are abundant components of the postsynaptic density (PSD) at excitatory synapses, play critical roles in synaptic structure, formation, development, plasticity, and signaling. The convergence of human genetic data with recent in vitro and in vivo animal model data indicates that mutations in the genes encoding SAPAP1–4 are associated with neurological and psychiatric disorders, and that dysfunction of SAPAP scaffolding proteins may contribute to the pathogenesis of various neuropsychiatric disorders, such as schizophrenia, autism spectrum disorders, obsessive compulsive disorders, Alzheimer’s disease, and bipolar disorder.

SAPAP neuropsychiatric disorders PSD mouse models

1. Expression of SAP90/PSD-95-Associated Proteins in the Central Nervous System

During postnatal development, the different SAP90/PSD-95-associated protein (SAPAP) members are expressed differently. The temporal patterns of Sapap1 and Sapap2 expression in individual brain regions do not change prominently after birth [1]. For example, the expression of Sapap1 mRNAs in the cortex seems to slightly peak around postnatal day 90. However, the spatiotemporal expression pattern of Sapap3 during early postnatal development is noticeable, with peak expression observed around 2–3 weeks after birth in the cortex, striatum, and thalamus [1][2]. Although high expression levels are seen in the cortex within the first 3 weeks after birth, the distribution of Sapap4 mRNA appears to slightly decline afterwards [1]. Additionally, recent studies have indicated that both Sapap1 and Sapap4 are expressed in progenitor cells—the latter notably strongly expressed in the cortical progenitors and migrating neurons—suggesting the important roles of SAPAPs during early corticogenesis [3][4].
In the adult rodent brain, the Sapap mRNAs and proteins display overlapping yet distinct distribution characteristics. All four Sapap mRNAs are expressed abundantly in the cerebral cortex, hippocampus, and olfactory bulb, but at low or undetectable levels in the hypothalamus and substantia nigra [1][5]. Sapap1 mRNA is expressed abundantly in the cortex, hippocampus, amygdala, cerebellum, and olfactory bulb, moderately in the thalamus, and at low levels in the striatum [5][6]. Notably, Sapap1 mRNA is only expressed in a small subset of cells in the striatum and displays heterogeneous expression patterns in different subregions of the thalamus [5], but it is uniformly distributed throughout the whole cerebral cortex.
Distinct from the other SAPAP family members, Sapap2 mRNAs are expressed in a limited pattern—mainly in the forebrain, with relatively low expression levels. Sapap2 displays its highest expression levels in the hippocampus, with moderate levels in the striatum and almost undetectable levels in the cerebellum, thalamus, and amygdala [5][6]. In the cortex, Sapap2 mRNAs show relative strong expression in layers 2 and 3 [5].
The most abundant Sapap detected in the striatum and various thalamic nuclei is Sapap3 [1][5]. Moreover, Sapap3 mRNAs are also highly expressed in layers 1–3 of the cortex, but only moderately expressed in the amygdala [5][6]. An intriguing aspect of the subcellular distribution of Sapap3 is its dendritic localization. It has been found that several mRNAs are localized in the dendrites [7][8], and an extensive body of literature directly linked synaptic plasticity with local protein synthesis and degradation in dendrites [9][10][11] (reviewed in [7][12][13][14]). In the hippocampus, Sapap3 is the only family member that is highly localized in dendrites [1][5], which possibly allows rapid turnover of proteins and thus provides a mechanism for quick, activity-dependent changes in synaptic protein complex composition [7][14][15], suggesting that SAPAP3 may play a unique role in synaptic plasticity.
Sapap4 is highly expressed in many regions of the brain, such as the hippocampus, cortex, amygdala, and cerebellum [5][6][16]. In the hippocampus, the expression of Sapap4 mRNA and proteins is relatively high in CA1 and CA3, but low in the dentate gyrus. Additionally, Sapap4 mRNA shows high expression in layer 5 of the cortex. In addition to these areas, Sapap4 is also strongly expressed in the adult rodent thalamus [5][17] and striatum [6][18]—second only to Sapap3. Of particular interest, Sapap4 mRNA is strongly expressed in the locus coeruleus [5] as well as the ventricular zone and migrating neurons [3].
In general, the SAPAP proteins are predominantly localized at glutamatergic and cholinergic synapses, and not at GABAergic or glycinergic synapses [5], suggesting that SAPAPs may be a general “core” postsynaptic component of excitatory synapses, but not of inhibitory synapses. Moreover, subsequent studies have found that SAPAP3 and SAPAP4 may tend to present at corticostriatal and thalamostriatal excitatory synapses, respectively [6][18]. These findings of molecular heterogeneity of SAPAPs at different synapses imply that SAPAP family members may be localized at synapses in a circuit-selective manner, and that the molecular specificity in SAPAP proteins attributes a unique and specific function to the SAPAP family members. A systematic analysis of the SAPAPs according to the subregions and developmental stages of the brain remains to be determined and would be important for understanding the functions of SAPAPs in the brain.

2. SAP90/PSD-95-Associated Proteins’ Expression, Fragile X Mental Retardation Protein, and Neuropsychiatric Disorders

Substantial studies have shown the genetic and epigenetic dysregulation of SAPAP genes in patients afflicted with psychiatric disorders or related animal models [19][20][21][22][23][24][25][26]. Fragile X mental retardation protein (FMRP) is considered to be a translational repressor that plays a key role in regulating local mRNA translation in response to synaptic signaling. In Fmr1-knockout (KO) mice—a model for fragile X syndrome—the protein levels of several FMRP targets are increased in PSD fractions either from the neocortex or hippocampus, including Sapap1–3, Shank1, Shank3, and various glutamate receptor subunits [27]. Conversely, Sapap3 is decreased in both the OFC and medial prefrontal cortex (mPFC) of Fmr1-KO mice [28], which may contribute to the deficits in cognitive flexibility found in fragile X syndrome. Additionally, aggressive experience also increases the expression of Sapap3, coupled with a decrease in FMRP phosphorylation that is dependent on the activation of mGluR5 [29]. The postsynaptic targets of FMRP also include Sapap4, mGluR5, and many other scaffold proteins that comprise the glutamate receptor interactomes, such as PSD-95, Homer1, and Neuroligins 1–3 [30][31][32]. The mRNA for Sapap4 is significantly increased by the activation of mGluRs in WT but not Fmr1-KO neurons [33]. Diminished mGluR-induced dendritic localization of Sapap4 mRNA is found in the hippocampal neurons of Fmr1-KO mice [33], indicating a surprising coordinate regulation between Sapap4 and mGluRs that may be altered in fragile X syndrome. In accordance with these findings, increased mGluR5-signaling-dependent AMPAR endocytosis or altered mGluR5–Homer scaffolds are observed in obsessive compulsive disorder (OCD) models with Sapap3-mutant mice, fragile X syndrome models with Fmr1-KO mice, and autism models with Shank3-mutant mice, which all include repetitive behaviors, among other symptoms [34][35][36][37], suggesting a potential shared genetic mechanism of different neuropsychiatric disorders (Figure 1).
Cells 11 03815 g002 550
Figure 1. Potential roles of SAPAPs in synaptic function and the pathogenesis of neuropsychiatric disorders. Hypothesized mechanisms of SAPAPs for the molecular signaling underlying OCD, ASD, Fragile X Syndrome, AD and other cognitive disorders are summarized in the figure. AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor; NMDAR, N-methyl-D-aspartic acid receptor; KCh, Shaker-type K+ channels; SAPAP, SAP90/PSD-95-associated protein; mGluR1/5, Group I metabotropic glutamate receptors; CaMKII, Calcium/calmodulin-dependent protein kinase II; PKC, Protein kinase C; SynGAP, Synaptic GTPase Activating Protein; nNOS, Neural Nitric Oxide Synthase; S-SCAM, synaptic scaffolding molecule; nArgBP2, Neural Abelson-related gene-binding protein 2; CBL, E3 ubiquitin ligase casitas B-lineage lymphoma; ABL, tyrosine kinase; PYK2, proline-rich tyrosine kinase 2; APP, amyloid precursor protein; P, phosphorylation; FMRP, fragile X mental retardation protein; TRIM3, Tripartite motif-containing 3; Ub, ubiquitin; DLC, dynein light-chain; CDK5, cyclin-dependent kinase 5; TRAP, transmembrane AMPAR regulatory protein.
Altered expression levels of SAPAPs are also observed in different neuropsychiatric disorders (Table 1). Sapap1 expression in the NAc is significantly increased in both animal models of phencyclidine-induced schizophrenia and unmedicated patients [25]. Sapap2 mRNA expression, which is significantly associated with its DNA methylation status, was associated with coping with stress in an animal model of post-traumatic stress disorder (PSTD) [22]. Similarly, the effects of Sapap2 methylation on memory ability in AD patients are also thought to be mediated by changes in SAPAP2 expression in the dorsal lateral prefrontal cortex (dlPFC) [20]. Increases in Sapap3 levels have been observed in both epilepsy patients and murine models [26]. Sapap4 has been indicated to be involved in psychostimulants’ actions and bipolar disorder (BD). In taste-aversion-resistant rats after cocaine exposure, the mRNA levels of Sapap4 in the amygdala were strikingly lower than those in taste-aversion-prone rats [38]. Remarkably, sensitivity to cocaine and amphetamine was also changed in Sapap4-deficient mice [17][39]. Interestingly, in human neural progenitor cells derived from BD patients, Sapap4 has been identified as a target gene of miR-1908-5p-a BD-associated epigenetic regulator [40]—suggesting that epigenetic dysregulation of SAPAP4 may be involved in the pathogenesis of BD.
Table 1. Changes of SAPAPs’ mRNA and/or protein expression associated with neuropsychiatric disorders.
Gene Regulation Expression Brain Regions Animal Models/Patients References
SAPAP1 Upregulation Protein Cortex or hippocampus Fmr1-KO mice [27]
Upregulation mRNA or protein Rats: NAc and hippocampus; patients: NAc Schizophrenia rat model and patients [25]
SAPAP2 Upregulation Protein Cortex or hippocampus Fmr1-KO mice [27]
SAPAP3 Upregulation Protein Cortex or hippocampus Fmr1-KO mice [27]
Upregulation mRNAor Protein NAc Syrian hamsters after aggressive experience [29]
Downregulation Protein OFC and mPFC Fmr1-KO mice [28]
Upregulation Protein Mice: cortex and hippocampus; patients: cortex Epilepsy patients and murine models [26]
SAPAP4 Upregulation in
the hippocampus		 mRNA Hippocampus Fmr1-KO mice [33]
Downregulation mRNA Amygdala Taste-aversion-resistant rats after cocaine exposure [38]
Epigenetic dysregulation of the expression of SAPAP genes, mainly mediated by changes in DNA methylation and histone acetylation, may confer risks of various neuropsychiatric disorders (Table 2). Epigenetic modifications of the Sapap2 gene have been implicated in PTSD [22], alcohol and cannabis use [19][24], schizophrenia [23], and AD [20]. One study revealed that histone deacetylases and methyl-CpG-binding protein 2 (MeCP2) inhibit repetitive behaviors through regulation of the Sapap3 gene [41]. Additionally, recent studies have also reported an association between altered methylation of SAPAP1 and stress responses to violence [42] and a link between epigenetic dysregulation of SAPAP4 and early-onset cerebellar ataxia [21][43].
Table 2. Epigenetic dysregulation of the expression of SAPAP genes associated with neuropsychiatric disorders.
Gene Regulation Expression Brain
Regions/Cells		 Animal
Models/Patients		 References
SAPAP2 Upregulation (with lower DNA methylation) mRNA Hippocampus PTSD rat model [22]
Upregulation (with lower DNA methylation) mRNA dlPFC or
NAc		 Patients with alcohol dependence [19]
Downregulation (related to DNA methylation) mRNA
protein		 dlPFC AD patients [20]
SAPAP3 Downregulation (by absence of histone deacetylases) mRNA Frontal cortex and striatum Mice deficient in histone deacetylases 1 and 2 [41]
SAPAP4 Disruption of SAPAP4 by the chromosome translocation results in monoallelic hypermethylation of the truncated SAPAP4 promoter CpG island N/A Cerebellum Early-onset cerebellar ataxia patients [21]
Identified as a target of the BD-associated microRNA miR-1908-5p N/A Neural progenitor cells BD patients [40]
Abbreviations: AD, Alzheimer’s disease; BD, bipolar disorder; PTSD, post-traumatic stress disorder.

3. Human Molecular Genetic Analysis of Neuropsychiatric Disorders Linked to SAP90/PSD-95-Associated Protein

3.1. SAPAP1 and Neuropsychiatric Disorders

Several human molecular genetic studies have emerged to show that SAPAP1 is related to several neuropsychiatric disorders, including schizophrenia, OCD, AD, ADHD, ASD, mood disorders, and cortical malformation [44][45][46][47][48][49][50][51][52] (Table 3). The SAPAP1 gene is located on chromosome 18p11, which has been suggested to be a susceptibility region for schizophrenia and/or BD [53][54]. Although several SNPs found in SAPAP1 are not associated with schizophrenia [49][50], a de novo CNV mutation of SAPAP1 has been identified in patients with schizophrenia [44]. The first genome-wide association study (GWAS) with 1465 OCD cases revealed that the two SNPs with the lowest p-values were located within SAPAP1, suggesting a subthreshold statistical significance for SAPAP1 [45]. Furthermore, the fact that two rare CNVs (a 62 kb duplication for SAPAP1 and a 16 kb deletion for SAPAP2) overlapping the FMRP targets SAPAP1 and SAPAP2 were uncovered in another OCD study is of particular interest [46]. Two SAPAP1 SNPs associated with cognitive flexibility have also been identified in ADHD children [47]. In addition, SAPAP1 is also implicated in ASD [51] and recurrent major depressive disorder (MDD) [52]. Interestingly, the expression of SAPAP1, which is significantly downregulated in the hippocampus and cortex of AD patients, is strongly associated with early identified AD variants (i.e., noncoding SNP rs8093731 in Desmoglein-2/DSG2 that acts as an expression quantitative trait loci for SAPAP1) [48] and SAPAP1 is identified as a potential candidate gene involved in AD.

3.2. SAPAP2 and Neuropsychiatric Disorders

Numerous studies have implicated SAPAP2 as being the strongest candidate gene for neurodevelopmental or behavioral phenotypes and closely associated with various neuropsychiatric disorders [20][46][55][56][57][58][59][60][61][62][63][64][65][66]. Strikingly, many genetic variants—including SNPs, single-nucleotide variants (SNVs), and de novo common and/or rare CNVs—in SAPAP2 have been found to be associated with neurodevelopmental disorders such as ASD and ADHD [56][57][58][59][60][61][62][63][64][67], cognitive disorders such as developmental delay (DD)/ID and AD [20][64][65][67], and other disorders, such as schizophrenia [55][57][61][68][69][70] and OCD [46][66].
Table 3. Genetic variants in SAPAP genes associated with neuropsychiatric disorders.
Gene Schizophrenia ASD OCD and Related Disorders AD and Other Cognitive Disorders ADHD and MDD
SAPAP1 Rare missense mutation c.1922A > G (a benign variant) [50] Associated with the IGAP (International Genomics of Alzheimer’s Project) SNP rs8093731 in Desmoglein-2/DSG2; underexpressed in the entorhinal cortex, hippocampus, and frontal and temporal cortex of AD cases [48] SNPs rs1116345 and rs34248 [66] c.1397A > G, p. Asp466Gly, exon 8 in subcortical heterotopias [3] SNPs rs2049161and rs16946051 associated with cognitive flexibility in ADHD [47]
SNP rs12455524 in recurrent MDD [52]
  De novo CNV deletion [44] Identified as an ASD-associated gene in a genome-wide network analysis [51] Two SNPs located within an intron of SAPAP1 [45] N/A N/A
  N/A N/A Rare CNVs (62 kb duplication) [46] N/A N/A
SAPAP2 Damaging missense [69] CNV 8:1626547:G:C [58] SNPs rs6558484 and rs7014992 associated with OFC white matter volume [66] 8p23.3 deletion in DD/mental retardation [67] N/A
  CNV duplication [68] Rare de novo CNV duplications(704383-1521910) [57] Rare CNVs (16 kb deletion) [46] SNP rs34130287C within the first intron [71] N/A
  SNV c.-69+9C.T, c.-69+13C.T, c.-69+47C.T, c.-69+55C.T [56] SNP rs2906569 at intron 1, rs2301963 (P384Q) at exon 3 and several nonsynonymous variants [59] N/A SNP rs6992443 [72] N/A
  N/A Rare de novo CMV duplication 8:704383-1521910 [60] N/A SNP rs2957061 SNP chr8:1316870; minor allele frequency (a locus within SAPAP2) [20] N/A
Gene Schizophrenia ASD OCD and Related Disorders AD and Other Cognitive Disorders
SAPAP2 CNV deletion, 8p 23.2 and 8p 23.1 [61] CNV deletion 8p 23.3 [73] N/A N/A
  N/A CNV deletion 8p 23.2 and 8p 23.1 [61] N/A N/A
  CNV deletion, 8p23.3-p23.1 [70] CNV duplication 8p23.3 (patients with de novo rearrangements) [62] N/A N/A
  N/A CNV duplication,8p23.3 (1, 499, 963–1, 854, 917) [63] N/A N/A
SAPAP3 SNVs
c.1141G > A; c.1759G > C;
c.2309G > T; c.2578-11C > T [56]		 CNV 1:35365700:G:A [58] Increased frequency of rare nonsynonymous coding variants (in OCD and TTM) [74] N/A
  N/A N/A SNPs rs6662980–rs4652867 in grooming disorder [75] N/A
  N/A N/A SNP rs11264126 and two
haplotypes containing rs11264126 and rs12141243 in TS [76]		 N/A
  N/A N/A SNPs rs11583978 and rs6682829 in early-onset OCD [77] N/A
SAPAP4 N/A SNP located at the 20q11.21–q13.12 locus comprising the Sapap4 gene [78] N/A De novo frameshift SNVs (c.2714_2715insCAGCTGG) insertion, N905Qfs, exon 12; c.2893T > G, p. Ser965Ala, exon 13 in subcortical heterotopias [3]
Abbreviations: ASD, autism spectrum disorder; OCD, obsessive–compulsive disorder; AD, Alzheimer’s disease; TTM, trichotillomania; MDD, major depressive disorder; OFC, orbitofrontal cortex; TS, Tourette syndrome; DD, developmental delay; ADHD, attention deficit hyperactivity disorder; SNPs, single-nucleotide polymorphisms; SNVs, single-nucleotide variants; CNVs, copy number variants.
Although SAPAP2 has been identified as a promising candidate gene of ASD, the potential role of SAPAP2 in ASD is still unclear. A study using a murine model demonstrated that the deletion of SAPAP2 leads to increased social interaction and aggressive behavior, along with impaired initial reverse learning and synaptic function [79], indicating that SAPAP2 somehow modulates cognition. Correspondingly, a recent cross-species study not only revealed the role of SAPAP2 in age-related working memory decline, but also established an association between SAPAP2 and AD phenotypes at multiple levels of analysis [20], highlighting the possible importance of epigenetic dysregulation of SAPAP2 expression in the pathophysiology of AD. As noted in the above studies, CDK5—one of the key kinases in AD—is involved in triggering amyloid-beta (Aβ)-induced ubiquitination and degradation of SAPAPs [80], while amyloid precursor protein (APP) is one of binding partners of Homer, which is indirectly linked to SAPAPs via SHANKs [81]. Gene overexpression can arise from de novo CNV duplication, and several autism risk genes in duplicated loci—such as SAPAP2, SHANK3, and Neuroligins 1 and 3—are all FMRP targets [27][31][57][60][62], suggesting a promising link between dysfunction of FMRP in regulating the expression of synaptic proteins and the development of ASD.

3.3. SAPAP3 and Neuropsychiatric Disorders

After the initial report of the features of Sapap3-mutant mice for OCD-like repetitive self-grooming behaviors [6], a higher frequency of rare nonsynonymous coding variants located in SAPAP3 was found in OCD patients, providing the first clinical evidence and tentatively supporting the link between SAPAP3 and OCD [74]. Several follow-up human genetic studies and other secondary analyses of GWAS have also noted that SAPAP3 is a promising functional candidate gene for OCD and obsessive–compulsive spectrum disorders, such as trichotillomania (TTM) and Tourette syndrome (TS) [74][75][76][77], although some of the mutations identified in the above studies are more commonly found in association with grooming disorders and TTM than with OCD. Convergent evidence from functional imaging and neuropsychological studies has linked OCD symptoms to dysfunction of striatum-based circuitry, especially highlighting cortico-striato-thalamo-cortical circuitry [75][82][83]. Owing to their robust behavioral similarities and sophisticated neural circuitry shared with OCD and related disorders [6][18], Sapap3-mutant mice are now considered to be a well-established animal model for OCD and related disorders. Interestingly, a CNV within the SAPAP3 gene was also identified in a study of about 200 individuals with ASD [58]—a spectrum of disorders that involve prominent compulsive-like repetitive behaviors overlapped with the behavioral phenotypes of OCD.

3.4. SAPAP4 and Neuropsychiatric Disorders

In addition to the aforementioned possible roles in the actions of psychostimulants, BD, and fragile X syndrome, SAPAP4 is also associated with several other neuropsychiatric disorders, including ASD, early-onset cerebellar ataxia, and subcortical heterotopias [3][21][78]. An SNP located at the 20q11.21–q13.12 locus that encompasses the SAPAP4 gene has also been linked with a potential role in the development of ASD [78]. SAPAP4 is also implicated in early-onset cerebellar ataxia, according to an epigenetic study in which disruption of the SAPAP4 gene by the chromosome translocation t (8;20) caused monoallelic DNA hypermethylation of the truncated SAPAP4 promoter CpG island 820 bp downstream of the first untranslated exon of SAPAP4 isoform a and perturbed expression of the SAPAP4 gene [21]. A recent study has identified a de novo frameshift variation and a missense variant in SAPAP4 from two families with different types of subcortical heterotopias—which are cortical malformations associated with ID and epilepsy [3]—pinpointing a novel role of SAPAP4 in early cortical development. Although there is only an indirect link between SAPAP4 and mood disorders such as BD [40], 22q13 duplications spanning SHANK3 (a known interaction scaffold protein of SAPAP4) have been found in patients diagnosed with ADHD and BD, respectively [84], suggesting a possible role of SAPAP4 in hyperkinetic disorders and mood disorders.

References

  1. Kindler, S.; Rehbein, M.; Classen, B.; Richter, D.; Bockers, T.M. Distinct spatiotemporal expression of SAPAP transcripts in the developing rat brain: A novel dendritically localized mRNA. Brain Res. Mol. Brain Res. 2004, 126, 14–21.
  2. Chua, J.J.; Schob, C.; Rehbein, M.; Gkogkas, C.G.; Richter, D.; Kindler, S. Synthesis of two SAPAP3 isoforms from a single mRNA is mediated via alternative translational initiation. Sci. Rep. 2012, 2, 484.
  3. Romero, D.M.; Poirier, K.; Belvindrah, R.; Moutkine, I.; Houllier, A.; LeMoing, A.G.; Petit, F.; Boland, A.; Collins, S.C.; Soiza-Reilly, M.; et al. Novel role of the synaptic scaffold protein Dlgap4 in ventricular surface integrity and neuronal migration during cortical development. Nat. Commun. 2022, 13, 2746.
  4. Polioudakis, D.; de la Torre-Ubieta, L.; Langerman, J.; Elkins, A.G.; Shi, X.; Stein, J.L.; Vuong, C.K.; Nichterwitz, S.; Gevorgian, M.; Opland, C.K.; et al. A single-cell transcriptomic atlas of human neocortical development during mid-gestation. Neuron 2019, 103, 785–801.e788.
  5. Welch, J.M.; Wang, D.; Feng, G. Differential mRNA expression and protein localization of the SAP90/PSD-95-associated proteins (SAPAPs) in the nervous system of the mouse. J. Comp. Neurol. 2004, 472, 24–39.
  6. Welch, J.M.; Lu, J.; Rodriguiz, R.M.; Trotta, N.C.; Peca, J.; Ding, J.D.; Feliciano, C.; Chen, M.; Adams, J.P.; Luo, J.; et al. Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature 2007, 448, 894–900.
  7. Hanus, C.; Schuman, E.M. Proteostasis in complex dendrites. Nat. Rev. Neurosci. 2013, 14, 638–648.
  8. Cajigas, I.J.; Tushev, G.; Will, T.J.; tom Dieck, S.; Fuerst, N.; Schuman, E.M. The local transcriptome in the synaptic neuropil revealed by deep sequencing and high-resolution imaging. Neuron 2012, 74, 453–466.
  9. Kang, H.; Schuman, E.M. A requirement for local protein synthesis in neurotrophin-induced hippocampal synaptic plasticity. Science 1996, 273, 1402–1406.
  10. Aakalu, G.; Smith, W.B.; Nguyen, N.; Jiang, C.; Schuman, E.M. Dynamic visualization of local protein synthesis in hippocampal neurons. Neuron 2001, 30, 489–502.
  11. Hegde, A.N.; Goldberg, A.L.; Schwartz, J.H. Regulatory subunits of cAMP-dependent protein kinases are degraded after conjugation to ubiquitin: A molecular mechanism underlying long-term synaptic plasticity. Proc. Natl. Acad. Sci. USA 1993, 90, 7436–7440.
  12. Steward, O.; Schuman, E.M. Compartmentalized synthesis and degradation of proteins in neurons. Neuron 2003, 40, 347–359.
  13. Cajigas, I.J.; Will, T.; Schuman, E.M. Protein homeostasis and synaptic plasticity. EMBO J. 2010, 29, 2746–2752.
  14. Mabb, A.M.; Ehlers, M.D. Ubiquitination in postsynaptic function and plasticity. Annu. Rev. Cell Dev. Biol. 2010, 26, 179–210.
  15. Ehlers, M.D. Activity level controls postsynaptic composition and signaling via the ubiquitin-proteasome system. Nat. Neurosci. 2003, 6, 231–242.
  16. Brenman, J.E.; Chao, D.S.; Gee, S.H.; McGee, A.W.; Craven, S.E.; Santillano, D.R.; Wu, Z.; Huang, F.; Xia, H.; Peters, M.F.; et al. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains. Cell 1996, 84, 757–767.
  17. Wang, T.; Bai, Y.; Zheng, X.; Liu, X.; Xing, S.; Wang, L.; Wang, H.; Feng, G.; Li, C. Sapap4 deficiency leads to postsynaptic defects and abnormal behaviors relevant to hyperkinetic neuropsychiatric disorder in mice. Cereb Cortex 2022.
  18. Wan, Y.; Ade, K.K.; Caffall, Z.; Ilcim Ozlu, M.; Eroglu, C.; Feng, G.; Calakos, N. Circuit-selective striatal synaptic dysfunction in the Sapap3 knockout mouse model of obsessive-compulsive disorder. Biol. Psychiatry 2014, 75, 623–630.
  19. Meng, W.; Sjoholm, L.K.; Kononenko, O.; Tay, N.; Zhang, D.; Sarkisyan, D.; Geske, J.R.; Ing, A.; Qiu, W.; Watanabe, H.; et al. Genotype-dependent epigenetic regulation of DLGAP2 in alcohol use and dependence. Mol. Psychiatry 2021, 26, 4367–4382.
  20. Ouellette, A.R.; Neuner, S.M.; Dumitrescu, L.; Anderson, L.C.; Gatti, D.M.; Mahoney, E.R.; Bubier, J.A.; Churchill, G.; Peters, L.; Huentelman, M.J.; et al. Cross-species analyses identify dlgap2 as a regulator of age-related cognitive decline and alzheimer’s dementia. Cell Rep. 2020, 32, 108091.
  21. Minocherhomji, S.; Hansen, C.; Kim, H.G.; Mang, Y.; Bak, M.; Guldberg, P.; Papadopoulos, N.; Eiberg, H.; Doh, G.D.; Mollgard, K.; et al. Epigenetic remodelling and dysregulation of DLGAP4 is linked with early-onset cerebellar ataxia. Hum. Mol. Genet. 2014, 23, 6163–6176.
  22. Chertkow-Deutsher, Y.; Cohen, H.; Klein, E.; Ben-Shachar, D. DNA methylation in vulnerability to post-traumatic stress in rats: Evidence for the role of the post-synaptic density protein Dlgap2. Int. J. Neuropsychopharmacol. 2010, 13, 347–359.
  23. Li, Y.; Wang, K.; Zhang, P.; Huang, J.; An, H.; Wang, N.; De Yang, F.; Wang, Z.; Tan, S.; Chen, S.; et al. Quantitative DNA methylation analysis of DLGAP2 gene using pyrosequencing in schizophrenia with tardive dyskinesia: A linear mixed model approach. Sci. Rep. 2018, 8, 17466.
  24. Schrott, R.; Acharya, K.; Itchon-Ramos, N.; Hawkey, A.B.; Pippen, E.; Mitchell, J.T.; Kollins, S.H.; Levin, E.D.; Murphy, S.K. Cannabis use is associated with potentially heritable widespread changes in autism candidate gene DLGAP2 DNA methylation in sperm. Epigenetics 2020, 15, 161–173.
  25. Kajimoto, Y.; Shirakawa, O.; Lin, X.H.; Hashimoto, T.; Kitamura, N.; Murakami, N.; Takumi, T.; Maeda, K. Synapse-associated protein 90/postsynaptic density-95-associated protein (SAPAP) is expressed differentially in phencyclidine-treated rats and is increased in the nucleus accumbens of patients with schizophrenia. Neuropsychopharmacology 2003, 28, 1831–1839.
  26. Zhang, Y.; Wu, J.; Yan, Y.; Gu, Y.; Ma, Y.; Wang, M.; Zhang, H.; Tao, K.; Lu, Y.; Yu, W.; et al. SAPAP3 regulates epileptic seizures involving GluN2A in post-synaptic densities. Cell Death Dis. 2022, 13, 437.
  27. Schutt, J.; Falley, K.; Richter, D.; Kreienkamp, H.J.; Kindler, S. Fragile X mental retardation protein regulates the levels of scaffold proteins and glutamate receptors in postsynaptic densities. J. Biol. Chem. 2009, 284, 25479–25487.
  28. Krueger, D.D.; Osterweil, E.K.; Chen, S.P.; Tye, L.D.; Bear, M.F. Cognitive dysfunction and prefrontal synaptic abnormalities in a mouse model of fragile X syndrome. Proc. Natl. Acad. Sci. USA 2011, 108, 2587–2592.
  29. Been, L.E.; Moore, K.M.; Kennedy, B.C.; Meisel, R.L. Metabotropic glutamate receptor and fragile X signaling in a female model of escalated aggression. Biol. Psychiatry 2016, 79, 685–692.
  30. Brown, V.; Jin, P.; Ceman, S.; Darnell, J.C.; O’Donnell, W.T.; Tenenbaum, S.A.; Jin, X.; Feng, Y.; Wilkinson, K.D.; Keene, J.D.; et al. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 2001, 107, 477–487.
  31. Darnell, J.C.; Klann, E. The translation of translational control by FMRP: Therapeutic targets for FXS. Nat. Neurosci. 2013, 16, 1530–1536.
  32. Bassell, G.J.; Warren, S.T. Fragile X syndrome: Loss of local mRNA regulation alters synaptic development and function. Neuron 2008, 60, 201–214.
  33. Dictenberg, J.B.; Swanger, S.A.; Antar, L.N.; Singer, R.H.; Bassell, G.J. A direct role for FMRP in activity-dependent dendritic mRNA transport links filopodial-spine morphogenesis to fragile X syndrome. Dev. Cell 2008, 14, 926–939.
  34. Wan, Y.; Feng, G.; Calakos, N. Sapap3 deletion causes mGluR5-dependent silencing of AMPAR synapses. J. Neurosci. 2011, 31, 16685–16691.
  35. Ade, K.K.; Wan, Y.; Hamann, H.C.; O’Hare, J.K.; Guo, W.; Quian, A.; Kumar, S.; Bhagat, S.; Rodriguiz, R.M.; Wetsel, W.C.; et al. Increased metabotropic glutamate receptor 5 signaling underlies obsessive-compulsive disorder-like behavioral and striatal circuit abnormalities in mice. Biol. Psychiatry 2016, 80, 522–533.
  36. Nakamoto, M.; Nalavadi, V.; Epstein, M.P.; Narayanan, U.; Bassell, G.J.; Warren, S.T. Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors. Proc. Natl. Acad. Sci. USA 2007, 104, 15537–15542.
  37. Wang, X.; Bey, A.L.; Katz, B.M.; Badea, A.; Kim, N.; David, L.K.; Duffney, L.J.; Kumar, S.; Mague, S.D.; Hulbert, S.W.; et al. Altered mGluR5-Homer scaffolds and corticostriatal connectivity in a Shank3 complete knockout model of autism. Nat. Commun. 2016, 7, 11459.
  38. Elkins, R.L.; Orr, T.E.; Rausch, J.L.; Fei, Y.J.; Carl, G.F.; Hobbs, S.H.; Buccafusco, J.J.; Edwards, G.L. Cocaine-induced expression differences in PSD-95/SAP-90-associated protein 4 and in Ca2+/calmodulin-dependent protein kinase subunits in amygdalae of taste aversion-prone and taste aversion-resistant rats. Ann. N. Y. Acad. Sci. 2003, 1003, 386–390.
  39. Wu, B.; Li, C.; Lei, H. SAPAP4 deletion causes synaptic dysfunction in the nucleus accumbens. Biochem. Biophys. Res. Commun. 2018, 505, 1223–1227.
  40. Kim, Y.; Zhang, Y.; Pang, K.; Kang, H.; Park, H.; Lee, Y.; Lee, B.; Lee, H.J.; Kim, W.K.; Geum, D.; et al. Bipolar disorder associated microRNA, miR-1908-5p, regulates the expression of genes functioning in neuronal glutamatergic synapses. Exp. Neurobiol. 2016, 25, 296–306.
  41. Mahgoub, M.; Adachi, M.; Suzuki, K.; Liu, X.; Kavalali, E.T.; Chahrour, M.H.; Monteggia, L.M. MeCP2 and histone deacetylases 1 and 2 in dorsal striatum collectively suppress repetitive behaviors. Nat. Neurosci. 2016, 19, 1506–1512.
  42. Saadatmand, F.; Gurdziel, K.; Jackson, L.; Kwabi-Addo, B.; Ruden, D.M. DNA methylation and exposure to violence among African American young adult males. Brain Behav. Immun. Health 2021, 14, 100247.
  43. Minocherhomji, S.; Seemann, S.; Mang, Y.; El-Schich, Z.; Bak, M.; Hansen, C.; Papadopoulos, N.; Josefsen, K.; Nielsen, H.; Gorodkin, J.; et al. Sequence and expression analysis of gaps in human chromosome 20. Nucleic Acids Res. 2012, 40, 6660–6672.
  44. Kirov, G.; Pocklington, A.J.; Holmans, P.; Ivanov, D.; Ikeda, M.; Ruderfer, D.; Moran, J.; Chambert, K.; Toncheva, D.; Georgieva, L.; et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol. Psychiatry 2012, 17, 142–153.
  45. Stewart, S.E.; Yu, D.; Scharf, J.M.; Neale, B.M.; Fagerness, J.A.; Mathews, C.A.; Arnold, P.D.; Evans, P.D.; Gamazon, E.R.; Davis, L.K.; et al. Genome-wide association study of obsessive-compulsive disorder. Mol. Psychiatry 2013, 18, 788–798.
  46. Gazzellone, M.J.; Zarrei, M.; Burton, C.L.; Walker, S.; Uddin, M.; Shaheen, S.M.; Coste, J.; Rajendram, R.; Schachter, R.J.; Colasanto, M.; et al. Uncovering obsessive-compulsive disorder risk genes in a pediatric cohort by high-resolution analysis of copy number variation. J. Neurodev. Disord. 2016, 8, 36.
  47. Fan, Z.; Qian, Y.; Lu, Q.; Wang, Y.; Chang, S.; Yang, L. DLGAP1 and NMDA receptor-associated postsynaptic density protein genes influence executive function in attention deficit hyperactivity disorder. Brain Behav. 2018, 8, e00914.
  48. Katsumata, Y.; Nelson, P.T.; Estus, S.; Alzheimer’s Disease Neuroimaging, I.; Fardo, D.W. Translating Alzheimer’s disease-associated polymorphisms into functional candidates: A survey of IGAP genes and SNPs. Neurobiol. Aging 2019, 74, 135–146.
  49. Aoyama, S.; Shirakawa, O.; Ono, H.; Hashimoto, T.; Kajimoto, Y.; Maeda, K. Mutation and association analysis of the DAP-1 gene with schizophrenia. Psychiatry Clin. Neurosci. 2003, 57, 545–547.
  50. Li, J.M.; Lu, C.L.; Cheng, M.C.; Luu, S.U.; Hsu, S.H.; Chen, C.H. Genetic analysis of the DLGAP1 gene as a candidate gene for schizophrenia. Psychiatry Res. 2013, 205, 13–17.
  51. Li, J.; Shi, M.; Ma, Z.; Zhao, S.; Euskirchen, G.; Ziskin, J.; Urban, A.; Hallmayer, J.; Snyder, M. Integrated systems analysis reveals a molecular network underlying autism spectrum disorders. Mol. Syst. Biol. 2014, 10, 774.
  52. Mathias, S.R.; Knowles, E.E.; Kent, J.W., Jr.; McKay, D.R.; Curran, J.E.; de Almeida, M.A.; Dyer, T.D.; Goring, H.H.; Olvera, R.L.; Duggirala, R.; et al. Recurrent major depression and right hippocampal volume: A bivariate linkage and association study. Hum. Brain Mapp. 2016, 37, 191–202.
  53. Mukherjee, O.; Meera, P.; Ghosh, S.; Kubendran, S.; Kiran, K.; Manjunath, K.R.; Subhash, M.N.; Benegal, V.; Brahmachari, S.K.; Majumder, P.P.; et al. Evidence of linkage and association on 18p11.2 for psychosis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2006, 141B, 868–873.
  54. Schwab, S.G.; Hallmayer, J.; Lerer, B.; Albus, M.; Borrmann, M.; Honig, S.; Strauss, M.; Segman, R.; Lichtermann, D.; Knapp, M.; et al. Support for a chromosome 18p locus conferring susceptibility to functional psychoses in families with schizophrenia, by association and linkage analysis. Am. J. Hum. Genet. 1998, 63, 1139–1152.
  55. Soler, J.; Fananas, L.; Parellada, M.; Krebs, M.O.; Rouleau, G.A.; Fatjo-Vilas, M. Genetic variability in scaffolding proteins and risk for schizophrenia and autism-spectrum disorders: A systematic review. J. Psychiatry Neurosci. 2018, 43, 223–244.
  56. Li, J.M.; Lu, C.L.; Cheng, M.C.; Luu, S.U.; Hsu, S.H.; Hu, T.M.; Tsai, H.Y.; Chen, C.H. Role of the DLGAP2 gene encoding the SAP90/PSD-95-associated protein 2 in schizophrenia. PLoS ONE 2014, 9, e85373.
  57. Pinto, D.; Pagnamenta, A.T.; Klei, L.; Anney, R.; Merico, D.; Regan, R.; Conroy, J.; Magalhaes, T.R.; Correia, C.; Abrahams, B.S.; et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature 2010, 466, 368–372.
  58. Iossifov, I.; O’Roak, B.J.; Sanders, S.J.; Ronemus, M.; Krumm, N.; Levy, D.; Stessman, H.A.; Witherspoon, K.T.; Vives, L.; Patterson, K.E.; et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature 2014, 515, 216–221.
  59. Chien, W.H.; Gau, S.S.; Liao, H.M.; Chiu, Y.N.; Wu, Y.Y.; Huang, Y.S.; Tsai, W.C.; Tsai, H.M.; Chen, C.H. Deep exon resequencing of DLGAP2 as a candidate gene of autism spectrum disorders. Mol. Autism 2013, 4, 26.
  60. Pinto, D.; Delaby, E.; Merico, D.; Barbosa, M.; Merikangas, A.; Klei, L.; Thiruvahindrapuram, B.; Xu, X.; Ziman, R.; Wang, Z.; et al. Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. Am. J. Hum. Genet. 2014, 94, 677–694.
  61. Autism Genome Project, C.; Szatmari, P.; Paterson, A.D.; Zwaigenbaum, L.; Roberts, W.; Brian, J.; Liu, X.Q.; Vincent, J.B.; Skaug, J.L.; Thompson, A.P.; et al. Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat. Genet. 2007, 39, 319–328.
  62. Marshall, C.R.; Noor, A.; Vincent, J.B.; Lionel, A.C.; Feuk, L.; Skaug, J.; Shago, M.; Moessner, R.; Pinto, D.; Ren, Y.; et al. Structural variation of chromosomes in autism spectrum disorder. Am. J. Hum. Genet. 2008, 82, 477–488.
  63. Woodbury-Smith, M.; Zarrei, M.; Wei, J.; Thiruvahindrapuram, B.; O’Connor, I.; Paterson, A.D.; Yuen, R.K.C.; Dastan, J.; Stavropoulos, D.J.; Howe, J.L.; et al. Segregating patterns of copy number variations in extended autism spectrum disorder (ASD) pedigrees. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2020, 183, 268–276.
  64. Catusi, I.; Garzo, M.; Capra, A.P.; Briuglia, S.; Baldo, C.; Canevini, M.P.; Cantone, R.; Elia, F.; Forzano, F.; Galesi, O.; et al. 8p23.2-pter microdeletions: Seven new cases narrowing the candidate region and review of the literature. Genes 2021, 12, 652.
  65. Shi, S.; Lin, S.; Chen, B.; Zhou, Y. Isolated chromosome 8p23.2pter deletion: Novel evidence for developmental delay, intellectual disability, microcephaly and neurobehavioral disorders. Mol. Med. Rep. 2017, 16, 6837–6845.
  66. Wu, K.; Hanna, G.L.; Easter, P.; Kennedy, J.L.; Rosenberg, D.R.; Arnold, P.D. Glutamate system genes and brain volume alterations in pediatric obsessive-compulsive disorder: A preliminary study. Psychiatry Res. 2013, 211, 214–220.
  67. Wu, Y.; Ji, T.; Wang, J.; Xiao, J.; Wang, H.; Li, J.; Gao, Z.; Yang, Y.; Cai, B.; Wang, L.; et al. Submicroscopic subtelomeric aberrations in Chinese patients with unexplained developmental delay/mental retardation. BMC Med. Genet. 2010, 11, 72.
  68. Guilmatre, A.; Dubourg, C.; Mosca, A.L.; Legallic, S.; Goldenberg, A.; Drouin-Garraud, V.; Layet, V.; Rosier, A.; Briault, S.; Bonnet-Brilhault, F.; et al. Recurrent rearrangements in synaptic and neurodevelopmental genes and shared biologic pathways in schizophrenia, autism, and mental retardation. Arch. Gen. Psychiatry 2009, 66, 947–956.
  69. Purcell, S.M.; Moran, J.L.; Fromer, M.; Ruderfer, D.; Solovieff, N.; Roussos, P.; O’Dushlaine, C.; Chambert, K.; Bergen, S.E.; Kahler, A.; et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature 2014, 506, 185–190.
  70. Costain, G.; Lionel, A.C.; Merico, D.; Forsythe, P.; Russell, K.; Lowther, C.; Yuen, T.; Husted, J.; Stavropoulos, D.J.; Speevak, M.; et al. Pathogenic rare copy number variants in community-based schizophrenia suggest a potential role for clinical microarrays. Hum. Mol. Genet. 2013, 22, 4485–4501.
  71. White, C.C.; Yang, H.S.; Yu, L.; Chibnik, L.B.; Dawe, R.J.; Yang, J.; Klein, H.U.; Felsky, D.; Ramos-Miguel, A.; Arfanakis, K.; et al. Identification of genes associated with dissociation of cognitive performance and neuropathological burden: Multistep analysis of genetic, epigenetic, and transcriptional data. PLoS Med. 2017, 14, e1002287.
  72. Chaudhry, M.; Wang, X.; Bamne, M.N.; Hasnain, S.; Demirci, F.Y.; Lopez, O.L.; Kamboh, M.I. Genetic variation in imprinted genes is associated with risk of late-onset Alzheimer’s disease. J. Alzheimers Dis. 2015, 44, 989–994.
  73. Chien, W.H.; Gau, S.S.; Wu, Y.Y.; Huang, Y.S.; Fang, J.S.; Chen, Y.J.; Soong, W.T.; Chiu, Y.N.; Chen, C.H. Identification and molecular characterization of two novel chromosomal deletions associated with autism. Clin. Genet. 2010, 78, 449–456.
  74. Zuchner, S.; Wendland, J.R.; Ashley-Koch, A.E.; Collins, A.L.; Tran-Viet, K.N.; Quinn, K.; Timpano, K.C.; Cuccaro, M.L.; Pericak-Vance, M.A.; Steffens, D.C.; et al. Multiple rare SAPAP3 missense variants in trichotillomania and OCD. Mol. Psychiatry 2009, 14, 6–9.
  75. Bienvenu, O.J.; Wang, Y.; Shugart, Y.Y.; Welch, J.M.; Grados, M.A.; Fyer, A.J.; Rauch, S.L.; McCracken, J.T.; Rasmussen, S.A.; Murphy, D.L.; et al. Sapap3 and pathological grooming in humans: Results from the OCD collaborative genetics study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2009, 150B, 710–720.
  76. Crane, J.; Fagerness, J.; Osiecki, L.; Gunnell, B.; Stewart, S.E.; Pauls, D.L.; Scharf, J.M.; Tourette Syndrome International Consortium for, G. Family-based genetic association study of DLGAP3 in Tourette Syndrome. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2011, 156B, 108–114.
  77. Boardman, L.; van der Merwe, L.; Lochner, C.; Kinnear, C.J.; Seedat, S.; Stein, D.J.; Moolman-Smook, J.C.; Hemmings, S.M. Investigating SAPAP3 variants in the etiology of obsessive-compulsive disorder and trichotillomania in the South African white population. Compr. Psychiatry 2011, 52, 181–187.
  78. Allen-Brady, K.; Miller, J.; Matsunami, N.; Stevens, J.; Block, H.; Farley, M.; Krasny, L.; Pingree, C.; Lainhart, J.; Leppert, M.; et al. A high-density SNP genome-wide linkage scan in a large autism extended pedigree. Mol. Psychiatry 2009, 14, 590–600.
  79. Jiang-Xie, L.F.; Liao, H.M.; Chen, C.H.; Chen, Y.T.; Ho, S.Y.; Lu, D.H.; Lee, L.J.; Liou, H.H.; Fu, W.M.; Gau, S.S. Autism-associated gene Dlgap2 mutant mice demonstrate exacerbated aggressive behaviors and orbitofrontal cortex deficits. Mol. Autism 2014, 5, 32.
  80. Roselli, F.; Livrea, P.; Almeida, O.F. CDK5 is essential for soluble amyloid beta-induced degradation of GKAP and remodeling of the synaptic actin cytoskeleton. PLoS ONE 2011, 6, e23097.
  81. de Bartolomeis, A.; Barone, A.; Buonaguro, E.F.; Tomasetti, C.; Vellucci, L.; Iasevoli, F. The Homer1 family of proteins at the crossroad of dopamine-glutamate signaling: An emerging molecular “Lego” in the pathophysiology of psychiatric disorders. A systematic review and translational insight. Neurosci. Biobehav. Rev. 2022, 136, 104596.
  82. Monteiro, P.; Feng, G. Learning from animal models of obsessive-compulsive disorder. Biol. Psychiatry 2016, 79, 7–16.
  83. Pauls, D.L.; Abramovitch, A.; Rauch, S.L.; Geller, D.A. Obsessive-compulsive disorder: An integrative genetic and neurobiological perspective. Nat. Rev. Neurosci. 2014, 15, 410–424.
  84. Han, K.; Holder, J.L., Jr.; Schaaf, C.P.; Lu, H.; Chen, H.; Kang, H.; Tang, J.; Wu, Z.; Hao, S.; Cheung, S.W.; et al. SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties. Nature 2013, 503, 72–77.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Neurosciences
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Yunxia Bai
,
Huimin Wang
, Chunxia Li（*Corresponding author）
View Times: 988
Revisions: 4 times (View History)
Update Date: 19 Dec 2022
Table of Contents
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    There is no comment~
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    ${ selectedItem.replyTextCharacter }/${ selectedItem.replyMaxCharacter }
    Submit
    Cancel
    Confirm
    Are you sure to Delete?
    Yes No
    Academic Video Service
    Feedback